Lypanosys

Lypanosys is a clinical-stage biopharmaceutical company focused on developing novel topical treatments for inflammatory skin conditions, with a primary emphasis on atopic dermatitis. Founded by PureTech Health, the company leverages the research of Dr. Charles Serhan into specialized pro-resolving mediators (SPMs) to address the underlying causes of inflammation. Its lead candidate, LYP-010, is a topical formulation of a naturally occurring fatty acid designed to promote the resolution of inflammation without the side effects associated with steroids or calcineurin inhibitors. Lypanosys aims to provide a safer, more effective long-term management solution for patients suffering from chronic dermatological disorders.